PL367217A1 - Nowe środki przeciwinfekcyjne - Google Patents
Nowe środki przeciwinfekcyjneInfo
- Publication number
- PL367217A1 PL367217A1 PL02367217A PL36721702A PL367217A1 PL 367217 A1 PL367217 A1 PL 367217A1 PL 02367217 A PL02367217 A PL 02367217A PL 36721702 A PL36721702 A PL 36721702A PL 367217 A1 PL367217 A1 PL 367217A1
- Authority
- PL
- Poland
- Prior art keywords
- infectives
- novel anti
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29671201P | 2001-06-07 | 2001-06-07 | |
US33642801P | 2001-10-29 | 2001-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL367217A1 true PL367217A1 (pl) | 2005-02-21 |
Family
ID=26969781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL02367217A PL367217A1 (pl) | 2001-06-07 | 2002-06-07 | Nowe środki przeciwinfekcyjne |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040147739A1 (pl) |
EP (1) | EP1401443A4 (pl) |
JP (1) | JP2005501007A (pl) |
KR (1) | KR20040006026A (pl) |
CN (1) | CN1535151A (pl) |
AR (1) | AR036081A1 (pl) |
BR (1) | BR0210205A (pl) |
CA (1) | CA2449770A1 (pl) |
CO (1) | CO5540308A2 (pl) |
CZ (1) | CZ20033326A3 (pl) |
HU (1) | HUP0400149A2 (pl) |
IL (1) | IL158992A0 (pl) |
MX (1) | MXPA03011329A (pl) |
NO (1) | NO20035428D0 (pl) |
PL (1) | PL367217A1 (pl) |
WO (1) | WO2002098424A1 (pl) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
ATE493408T1 (de) * | 2002-11-01 | 2011-01-15 | Abbott Lab | Antiinfektiöse mittel |
BR0315897A (pt) * | 2002-11-01 | 2008-05-13 | Abbott Lab | agentes antiinfecciosos |
US7902203B2 (en) | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
WO2005019191A2 (en) * | 2003-08-25 | 2005-03-03 | Abbott Laboratories | 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c |
DK1680137T3 (da) | 2003-10-14 | 2013-02-18 | Hoffmann La Roche | Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
CA2549851C (en) | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
US7582770B2 (en) | 2004-02-20 | 2009-09-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
BRPI0514591A (pt) | 2004-08-23 | 2008-06-17 | Hoffmann La Roche | compostos antivirais heterocìclicos |
AU2005316396A1 (en) | 2004-12-17 | 2006-06-22 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
PL1831152T3 (pl) | 2004-12-21 | 2009-03-31 | Hoffmann La Roche | Pochodne tetraliny i indanu oraz ich zastosowanie jako antagonistów 5-HT |
EP1830871A1 (en) * | 2004-12-23 | 2007-09-12 | Novartis AG | Compositions for hcv treatment |
WO2006093801A1 (en) * | 2005-02-25 | 2006-09-08 | Abbott Laboratories | Thiadiazine derivatives useful as anti-infective agents |
BRPI0611388A2 (pt) | 2005-05-04 | 2010-09-08 | Hoffmann La Roche | compostos antivirais heterocìclicos, uso dos mesmos e composição farmacêutica |
AP2007004245A0 (en) | 2005-05-13 | 2007-12-31 | Virochem Pharma Inc | Compounds and methods for the treatment or prevention of flavivirus infections |
CN1319531C (zh) * | 2005-06-08 | 2007-06-06 | 复旦大学 | 喹啉类生物碱在制备抗乙肝病毒药物中的用途 |
WO2007051735A1 (en) | 2005-11-03 | 2007-05-10 | F. Hoffmann-La Roche Ag | Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors |
ES2355945T3 (es) | 2006-02-17 | 2011-04-01 | F. Hoffmann-La Roche Ag | Compuestos antivíricos heterocíclicos. |
CN101501039B (zh) | 2006-06-22 | 2012-02-22 | 安那迪斯药品股份有限公司 | 吡咯并[1,2-b]哒嗪酮化合物 |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
WO2008043704A1 (en) | 2006-10-10 | 2008-04-17 | Medivir Ab | Hcv nucleoside inhibitor |
NZ576780A (en) | 2006-11-15 | 2011-12-22 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
CL2007003587A1 (es) | 2006-12-12 | 2008-07-04 | Anadys Pharmaceuticals Inc | Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c. |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
US7834009B2 (en) | 2007-08-27 | 2010-11-16 | Anadys Pharmaceuticals, Inc. | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds |
WO2010002428A2 (en) | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
TWI438206B (zh) | 2008-06-10 | 2014-05-21 | Anadys Pharmaceuticals Inc | 〔1,2,4〕噻二1,1二氧化物化合物 |
ES2625817T3 (es) | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
EP3025727A1 (en) | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
WO2010042834A1 (en) | 2008-10-09 | 2010-04-15 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
TW201026675A (en) | 2008-10-09 | 2010-07-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
EP2403844A1 (en) | 2009-03-06 | 2012-01-11 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
EP2408449A4 (en) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
EP2421831A1 (en) | 2009-04-25 | 2012-02-29 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
JP2012527420A (ja) * | 2009-05-20 | 2012-11-08 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ウイルス性複素環化合物 |
EP2445875A2 (en) | 2009-06-24 | 2012-05-02 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compound |
CN102498100A (zh) | 2009-09-21 | 2012-06-13 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
CN102858344A (zh) | 2009-10-28 | 2013-01-02 | 安那迪斯药品股份有限公司 | 氘化5,6-二氢-1h-吡啶-2-酮化合物 |
KR20120104239A (ko) | 2009-11-14 | 2012-09-20 | 에프. 호프만-라 로슈 아게 | Hcv 치료에 대한 신속한 반응을 예측하기 위한 바이오마커 |
JP2013511489A (ja) | 2009-11-21 | 2013-04-04 | エフ.ホフマン−ラ ロシュ アーゲー | 複素環式抗ウイルス化合物 |
JP2013512247A (ja) | 2009-11-25 | 2013-04-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染症の治療または予防のための5−アルキニル−チオフェン−2−カルボン酸誘導体およびそれらの使用 |
EP2507636A1 (en) | 2009-12-02 | 2012-10-10 | F. Hoffmann-La Roche AG | Biomarkers for predicting sustained response to hcv treatment |
EP2515902A1 (en) | 2009-12-24 | 2012-10-31 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
JP5883397B2 (ja) | 2010-02-03 | 2016-03-15 | ビオマリン プハルマセウトイカル インコーポレイテッド | Pten欠損に関連した疾患の治療におけるポリ(adpリボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤の使用 |
KR101826652B1 (ko) | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | 디히드로피리도프탈라지논 유도체의 합성 방법 |
TW201139438A (en) | 2010-03-24 | 2011-11-16 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
EP2550278A1 (en) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
CA2794145A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
EP2550268A1 (en) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
WO2011159826A2 (en) | 2010-06-15 | 2011-12-22 | Vertex Pharmaceuticals Incorporated | Hcv ns5b protease mutants |
UY33473A (es) | 2010-06-28 | 2012-01-31 | Vertex Pharma | Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus |
WO2012006070A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
EP2585448A1 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
AU2011292040A1 (en) | 2010-08-17 | 2013-03-07 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of Flaviviridae viral infections |
TWI557123B (zh) | 2010-10-21 | 2016-11-11 | 梅迪維新技術公司 | 結晶型(8S,9R)-5-氟-8-(4-氟苯基)-9-(1-甲基-1H-1,2,4-三唑-5-基)-8,9-二氫-2H-吡啶并[4,3,2-de]呔-3(7H)-酮甲苯磺酸鹽 |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US20120321590A1 (en) | 2011-04-06 | 2012-12-20 | Anadys Pharmaceuticals, Inc. | Bridged polycyclic compounds |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
WO2013016492A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
WO2014134251A1 (en) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
RU2534613C2 (ru) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения |
CN113773277B (zh) * | 2021-09-18 | 2023-12-05 | 兰州大学 | 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19829978A1 (de) * | 1998-07-04 | 2000-01-05 | Agfa Gevaert Ag | Farbfotografisches Silberhalogenidmaterial |
JP2004509066A (ja) * | 2000-05-10 | 2004-03-25 | スミスクライン・ビーチャム・コーポレイション | 新規抗感染症薬 |
-
2002
- 2002-06-05 AR ARP020102090A patent/AR036081A1/es not_active Application Discontinuation
- 2002-06-07 MX MXPA03011329A patent/MXPA03011329A/es unknown
- 2002-06-07 IL IL15899202A patent/IL158992A0/xx unknown
- 2002-06-07 CA CA002449770A patent/CA2449770A1/en not_active Abandoned
- 2002-06-07 CZ CZ20033326A patent/CZ20033326A3/cs unknown
- 2002-06-07 PL PL02367217A patent/PL367217A1/pl not_active Application Discontinuation
- 2002-06-07 WO PCT/US2002/018491 patent/WO2002098424A1/en not_active Application Discontinuation
- 2002-06-07 KR KR10-2003-7016014A patent/KR20040006026A/ko not_active Application Discontinuation
- 2002-06-07 EP EP02744287A patent/EP1401443A4/en not_active Withdrawn
- 2002-06-07 CN CNA02814662XA patent/CN1535151A/zh active Pending
- 2002-06-07 US US10/479,358 patent/US20040147739A1/en not_active Abandoned
- 2002-06-07 HU HU0400149A patent/HUP0400149A2/hu unknown
- 2002-06-07 JP JP2003501463A patent/JP2005501007A/ja not_active Withdrawn
- 2002-06-07 BR BR0210205-6A patent/BR0210205A/pt not_active Application Discontinuation
-
2003
- 2003-12-05 NO NO20035428A patent/NO20035428D0/no not_active Application Discontinuation
- 2003-12-05 CO CO03107115A patent/CO5540308A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0400149A2 (hu) | 2004-07-28 |
BR0210205A (pt) | 2004-09-14 |
KR20040006026A (ko) | 2004-01-16 |
CA2449770A1 (en) | 2002-12-12 |
WO2002098424A1 (en) | 2002-12-12 |
US20040147739A1 (en) | 2004-07-29 |
IL158992A0 (en) | 2004-05-12 |
MXPA03011329A (es) | 2004-03-19 |
AR036081A1 (es) | 2004-08-11 |
WO2002098424B1 (en) | 2004-02-26 |
CZ20033326A3 (cs) | 2004-11-10 |
NO20035428D0 (no) | 2003-12-05 |
JP2005501007A (ja) | 2005-01-13 |
EP1401443A1 (en) | 2004-03-31 |
CN1535151A (zh) | 2004-10-06 |
CO5540308A2 (es) | 2005-07-29 |
EP1401443A4 (en) | 2005-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL158992A0 (en) | Novel anti-infectives | |
HU0401339D0 (en) | Novel 4-anilinoquinoline-3-carboxamides | |
AU2002365198A1 (en) | Novel anti-infectives | |
EP1387687A4 (en) | NEW USE | |
AU2003300957A8 (en) | Anti-infectives | |
AU2003297235A8 (en) | Anti-infectives | |
GB0115181D0 (en) | Novel use | |
GB0100762D0 (en) | Novel use | |
GB0104948D0 (en) | Novel methods | |
AU2003300956A8 (en) | Anti-infectives | |
AU2002360430A8 (en) | 14-methyl-epothilones | |
AU2002359464A8 (en) | Angiopioetin related factors | |
EP1384783A4 (en) | NEW MAXIZYM | |
EG23036A (en) | Novel pyrrolecarboxamides | |
GB0124577D0 (en) | Novel methods | |
GB0110338D0 (en) | Novel processes | |
AU2002313943A8 (en) | Electromobile | |
PL367864A1 (pl) | Nowa kombinacja | |
PL364076A1 (pl) | Nowe pirydylometyloaminopirymidyny | |
AU2001100134A4 (en) | Enviro-trap | |
GB0119169D0 (en) | Novel pyridyl-piperazines | |
CA92665S (en) | Bedboard | |
AU2479P (en) | Crackerjack xTriticosecale | |
CA92978S (en) | Photo-changer | |
AU2288P (en) | Prime322 xTriticosecale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |